Choose your country to see the products for your location

P213 HSP mix-2

SALSA® MLPA® Probemix P213 HSP mix-2 detects copy number variations in the REEP1 and SPG7 genes.

Specifications

Contents: 42 MLPA probes, including 10 probes for the REEP1 region and 21 probes for the SPG7 region.

Tissue: genomic DNA isolated from human peripheral whole blood.

Application: spastic paraplegia type 7 (SPG7) and type 31 (SPG31).

IVDR certified for in vitro diagnostic (IVD) use.

Quick links

List Prices Documentation

Key related products

P165 HSP mix-1

Targets SPAST, and the ALT1 region, involved in spastic paraplegia type 4.

P211 HSP region

Targets SPAST, the 2p22.3 region, and the 15q11.2 region, involved in heteritary spastic paraplegias (HSPs).

P306 SPG11

Targets SPG11, involved in spastic paraplegia 11 (SPG11).

View all

This product has recently been CE-marked for in vitro diagnostic (IVD) use under the In Vitro Diagnostic Regulation (IVDR; EU 2017/746), which replaces the former CE-marking under the IVD Directive (IVDD; Directive 98/79/EC). This update was accompanied by a change in the intended purpose and a change in format of the product description. Some information can now be found in a different location (more information).

Intended purpose

The SALSA MLPA Probemix P213 HSP mix-2 is an in vitro diagnostic (IVD) or research use only (RUO) semi-quantitative manual assay for the detection of deletions in REEP1 and SPG7 genes, in order to confirm a potential cause for and clinical diagnosis of spastic paraplegia (SPG) type 31 and SPG type 7, respectively and for molecular genetic testing of at-risk family members. This assay is for use with genomic DNA isolated from human peripheral whole blood specimens.

For the full intended purpose, see the product description.

Clinical background

Hereditary spastic paraplegias (HSP) are genetically heterogeneous neurodegenerative disorders characterised by progressive spasticity and weakness of the lower limbs due to axonal degeneration in the pyramidal tract. To date, more than 80 genetic types of HSP have been defined by genetic linkage analysis and identification of HSP-related gene variants.

Spastic paraplegia type 31 (SPG31) is caused by a pathogenic variant in the receptor expression-enhancing protein 1 (REEP1) and accounts for about 5% of all autosomal dominant HSP. The most common type of REEP1 mutations explaining SPG31 are small frameshift mutations, but nonsense, missense, and microRNA target site alterations have been described (Beetz et al. 2008). 9.5% of pathogenic mutations in REEP1 are copy number variations (Goizet et al. 2011).

SPG7 is caused by pathogenic variants in SPG7 and may account for approximately 5% of all autosomal recessive HSP. Of all SPG7 cases, most are caused by SPG7 point mutations (~98%), while less than 2% can be explained by SPG7 copy number variations (Klebe et al. 2012, Pfeffer et al. 2015).

More information on HSP is available on https://www.ncbi.nlm.nih.gov/books/NBK1509/.

Regulatory status

SALSA MLPA Probemix P213 HSP mix-2 is CE-marked under the IVDR for in vitro diagnostic (IVD) use in Europe.

This assay is for research use only (RUO) in all other territories.

Product documentation

Version B3

Other versions

Contact us for earlier versions.

Translations and Summary of Safety and Performance

Translations of the product description in selected European languages are available upon request. Please contact us or one of our local sales partners. Translations of the MLPA General Protocol in selected languages are available here.

The Summary of Safety and Performance (SSP) is also available upon request.

List prices

Product

Item no.
Description
Technology
Price
P213-025R
SALSA MLPA Probemix P213 HSP mix-2 – 25 rxn
MLPA
€ 286.00
P213-050R
SALSA MLPA Probemix P213 HSP mix-2 – 50 rxn
MLPA
€ 560.00
P213-100R
SALSA MLPA Probemix P213 HSP mix-2 – 100 rxn
MLPA
€ 1096.00

Required reagents

A general SALSA MLPA Reagent Kit is required for MLPA experiments (to be ordered separately).

Item no.
Description
Technology
Price
EK1-FAM
SALSA MLPA Reagent Kit – 100 rxn – FAM (6 vials)
MLPA MS-MLPA
€ 348.00
EK1-Cy5
SALSA MLPA Reagent Kit – 100 rxn – Cy5 (6 vials)
MLPA MS-MLPA
€ 348.00
EK5-FAM
SALSA MLPA Reagent Kit – 500 rxn – FAM (5×6 vials)
MLPA MS-MLPA
€ 1600.00
EK5-Cy5
SALSA MLPA Reagent Kit – 500 rxn – Cy5 (5×6 vials)
MLPA MS-MLPA
€ 1600.00
EK20-FAM
SALSA MLPA Reagent Kit – 2000 rxn – FAM (5×6 vials)
MLPA MS-MLPA
€ 6152.00

Price details & ordering

The prices above are list prices for direct orders from MRC Holland. Contact us for a quote that takes discounts and additional costs (such as shipping costs) into account. Different prices apply for orders through one of our sales partners; contact your local supplier for a quote.

More information about ordering & prices

Positive samples

Inclusion of a positive sample is usually not required, but can be useful for the analysis of your experiments. MRC Holland has very limited access to positive samples and cannot supply such samples. We recommend using positive samples from your own collection. Alternatively, you can use positive samples from an online biorepository, such as the Coriell Institute.

The commercially available positive samples below have been tested with the current (B3) version of this product and have been shown to produce useful results.

  • Coriell HG00246: Heterozygous triplication affecting the probes for REEP1 exon 3-8.
  • Coriell HG02128: Heterozygous deletion affecting the probes for SPG7 exon 1-7. The upstream flanking probe is also affected.
  • Coriell NA21108: Heterozygous duplication affecting the probes for SPG7. The upstream flanking probe is also affected.

Resources

General MLPA resources

MLPA education

Publications

Selected publications using P213 HSP mix-2

  • Arnoldi A et al. (2008). A clinical, genetic, and biochemical characterization of SPG7 mutations in a large cohort of patients with hereditary spastic paraplegia. Hum Mutat. 29:522-31.
  • Battini R et al. (2011). Clinical and genetic findings in a series of Italian children with pure hereditary spastic paraplegia. Eur J Neurol. 18:150-7.
  • Goizet C et al. (2011). REEP1 mutations in SPG31: frequency, mutational spectrum, and potential association with mitochondrial morpho-functional dysfunction. Hum Mutat. 32:1118-27.
  • López E et al. (2015). Characterization of Alu and recombination-associated motifs mediating a large homozygous SPG7 gene rearrangement causing hereditary spastic paraplegia. Neurogenetics. 16:97-105.
  • Pennings M et al. (2023). Copy number variants from 4800 exomes contribute to ~7% of genetic diagnoses in movement disorders, muscle disorders and neuropathies. Eur J Hum Genet. 31:654-62.
  • Yoon G et al. (2013). Autosomal recessive hereditary spastic paraplegia-clinical and genetic characteristics of a well-defined cohort. Neurogenetics. 14:181-8.

References

  • Beetz C et al. (2008). REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. Brain. 131:1078-86.
  • Goizet C et al. (2011). REEP1 mutations in SPG31: frequency, mutational spectrum, and potential association with mitochondrial morpho-functional dysfunction. Hum Mutat. 32:1118-27.
  • Klebe S et al. (2012). Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy. Brain. 135:2980-93.
  • Pfeffer G et al. (2015). SPG7 mutations are a common cause of undiagnosed ataxia. Neurology. 84:1174-6.
This site uses cookies to help improve your online experience. Learn more
No, thank you accept

Sign in

Don't have an account? Create one

Forgot password?

Select Your Country

Choose your country to see the products for your location

CE

CE-marked products are for In Vitro Diagnostic (IVD) use only in EU (candidate) member states and members of the European Free Trade Association (EFTA), and the UK.

CE2797

CE-marked products are for In Vitro Diagnostic (IVD) use only in EU (candidate) member states and members of the European Free Trade Association (EFTA), and the UK.